Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

Zikani Therapeutics Inc. hired Vijay Modur as chief scientific and medical officer. He was global project head in rare disease clinical development at the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Zikani is developing ribosome modulating agents to treat rare, nonsense mutation-driven diseases.

Growth factor modulation company Scholar Rock Holding Corp. (NASDAQ:SRRK) said Ted Myles, a member of the board, will become CFO and head of business operations. He succeeds Rhonda Chicko, who stepped down as CFO in October. Myles is the second member of the biotech’s board to announce this week they will take on an operational role. Tony Kingsley will become president and CEO after CEO Nagesh Mahanthappa steps down on Aug. 1...